CLINUVEL are determined in our desire to excel in scientific research and development, building on our global expertise to deliver longitudinal care and novel products for patients and consumers.
The CLINUVEL Group works to translate scientific concepts and breakthroughs into commercial products.
We are determined in our desire to excel scientific research and development, building on our global expertise to deliver lifelong care and novel products for patients and consumers.
The CLINUVEL Group places much emphasis on its People and Environment as central to all of the Group’s working practice. CLINUVEL focuses its research and development on healthcare problems not yet addressed, aiming to deliver innovative medical solutions. Our products seek to prevent or treat acute and chronic medical conditions where no alternatives exist
CLINUVEL launches CYACÊLLE polychromatic screen, its first PhotoCosmetic product.
CLINUVEL announces the development of PRÉNUMBRA® a non-solid (liquid) formulation of afamelanotide for the treatment of acute disorders.
The US Food and Drug Administration (FDA) grants marketing authorization for SCENESSE® (afamelanotide) for adult erythropoietic protoporphyria (EPP) patients.
The European Medicines Agency grants marketing authorisation for SCENESSE® (afamelanotide 16mg) for the prevention of phototoxicity in adult EPP patients.
CLINUVEL conducts its first clinical trial of afamelanotide in adult EPP patients.
A new management team refocuses CLINUVEL on the development of afamelanotide as a therapeutic.
An Australian team acquires the rights to the alpha-MSH analogue afamelanotide and lists on the Australian Securities Exchange.
A US team begins to investigate the properties of alpha-melanocyte stimulating hormone (alpha-MSH) and analogues for their potential as therapeutics.
We study melanocortins and their interaction with the body. We then look to turn this research into pharmaceutical and PhotoCosmetic products. Within this specialist field of medicine we have specialised further into products that work primarily with skin and the central nervous system. This research has lead to expertise in the following topics:
- The interaction of visible and UV light and human biology
- The family of peptides known as melanocortins and their analogues
- The effect of hormonal therapies on anti-inflammatory and nervous disorders
- Controlled-release pharmaceutical formulations